A planned assessment, not results
The primary objective is to assess the effects of these two transthyretin-stabilizing drugs on all-cause mortality and hospitalizations for heart failure in people with ATTR-CM.
The planned comparator is usual care or a placebo. The abstract does not describe a direct comparison between tafamidis and acoramidis. It therefore cannot establish which would be preferable.
Differences between patients will be examined
The authors also plan to examine effects by sex, ethnicity, disease form and severity. In particular, they will distinguish between wild-type and variant transthyretin forms, as well as NYHA functional classes.
These analyses are stated objectives. Their inclusion in the protocol does not guarantee that the available studies will support conclusions for each of these subgroups.
What this publication changes
Its contribution is to make the framework for the upcoming assessment explicit. The abstract consulted provides no pooled results, total participant count, follow-up duration or summary of adverse effects.
This publication is therefore not enough to justify changing a treatment or concluding that there is no benefit. It concerns medicines, not dietary supplements.
Limitations to keep in mind
Only the protocol’s PubMed abstract was consulted, not the full text. It presents no efficacy or safety results. Funding and conflicts of interest were not checked.
What we can take away
Takeaway: this protocol announces an assessment of two treatments for ATTR-CM, but does not yet demonstrate their benefits or whether either is superior to the other.
Sources and provenance
- TTR-stabilising medicines for the treatment of transthyretin amyloid cardiomyopathy.
Source date: 2026-11-20.
Journal Article, Systematic Review · Résumé PubMed uniquement, texte intégral non consulté


